Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Ischemic Stroke and Bleeding: Clinical Benefit of Anticoagulation in Atrial Fibrillation After Intracerebral Hemorrhage.

Stanton RJ, Eckman MH, Woo D, Moomaw CJ, Haverbusch M, Flaherty ML, Kleindorfer DO.

Stroke. 2020 Jan 31:STROKEAHA119027370. doi: 10.1161/STROKEAHA.119.027370. [Epub ahead of print]

PMID:
32000590
2.

Human cytomegalovirus interactome analysis identifies degradation hubs, domain associations and viral protein functions.

Nobre LV, Nightingale K, Ravenhill BJ, Antrobus R, Soday L, Nichols J, Davies JA, Seirafian S, Wang EC, Davison AJ, Wilkinson GW, Stanton RJ, Huttlin EL, Weekes MP.

Elife. 2019 Dec 24;8. pii: e49894. doi: 10.7554/eLife.49894.

3.

IL-33 Augments Virus-Specific Memory T Cell Inflation and Potentiates the Efficacy of an Attenuated Cytomegalovirus-Based Vaccine.

McLaren JE, Clement M, Marsden M, Miners KL, Llewellyn-Lacey S, Grant EJ, Rubina A, Gimeno Brias S, Gostick E, Stacey MA, Orr SJ, Stanton RJ, Ladell K, Price DA, Humphreys IR.

J Immunol. 2019 Feb 1;202(3):943-955. doi: 10.4049/jimmunol.1701757.

4.

HCMV-Encoded NK Modulators: Lessons From in vitro and in vivo Genetic Variation.

Patel M, Vlahava VM, Forbes SK, Fielding CA, Stanton RJ, Wang ECY.

Front Immunol. 2018 Oct 1;9:2214. doi: 10.3389/fimmu.2018.02214. eCollection 2018. Review.

5.

High-Definition Analysis of Host Protein Stability during Human Cytomegalovirus Infection Reveals Antiviral Factors and Viral Evasion Mechanisms.

Nightingale K, Lin KM, Ravenhill BJ, Davies C, Nobre L, Fielding CA, Ruckova E, Fletcher-Etherington A, Soday L, Nichols H, Sugrue D, Wang ECY, Moreno P, Umrania Y, Huttlin EL, Antrobus R, Davison AJ, Wilkinson GWG, Stanton RJ, Tomasec P, Weekes MP.

Cell Host Microbe. 2018 Sep 12;24(3):447-460.e11. doi: 10.1016/j.chom.2018.07.011. Epub 2018 Aug 16.

6.

Neurologic Abnormalities After Atrial Fibrillation Ablative Procedure.

Stanton RJ, Roesch MJ, Kanter D.

JAMA Neurol. 2018 Sep 1;75(9):1144-1145. doi: 10.1001/jamaneurol.2018.1351. No abstract available.

PMID:
29889931
7.

Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses.

Wang ECY, Pjechova M, Nightingale K, Vlahava VM, Patel M, Ruckova E, Forbes SK, Nobre L, Antrobus R, Roberts D, Fielding CA, Seirafian S, Davies J, Murrell I, Lau B, Wilkie GS, Suárez NM, Stanton RJ, Vojtesek B, Davison A, Lehner PJ, Weekes MP, Wilkinson GWG, Tomasec P.

Proc Natl Acad Sci U S A. 2018 May 8;115(19):4998-5003. doi: 10.1073/pnas.1720950115. Epub 2018 Apr 24.

8.

The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus.

Murrell I, Bedford C, Ladell K, Miners KL, Price DA, Tomasec P, Wilkinson GWG, Stanton RJ.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6104-6109. doi: 10.1073/pnas.1704809114. Epub 2017 May 22.

9.

Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation.

Fielding CA, Weekes MP, Nobre LV, Ruckova E, Wilkie GS, Paulo JA, Chang C, Suárez NM, Davies JA, Antrobus R, Stanton RJ, Aicheler RJ, Nichols H, Vojtesek B, Trowsdale J, Davison AJ, Gygi SP, Tomasec P, Lehner PJ, Wilkinson GW.

Elife. 2017 Feb 10;6. pii: e22206. doi: 10.7554/eLife.22206.

10.

Nanotextured Surface on Flexographic Printed ZnO Thin Films for Low-Cost Non-Faradaic Biosensors.

Assaifan AK, Lloyd JS, Samavat S, Deganello D, Stanton RJ, Teng KS.

ACS Appl Mater Interfaces. 2016 Dec 14;8(49):33802-33810. Epub 2016 Dec 1.

PMID:
27960397
11.

The contribution of pUL74 to growth of human cytomegalovirus is masked in the presence of RL13 and UL128 expression.

Laib Sampaio K, Stegmann C, Brizic I, Adler B, Stanton RJ, Sinzger C.

J Gen Virol. 2016 Aug;97(8):1917-1927. doi: 10.1099/jgv.0.000475. Epub 2016 Apr 6.

12.

Human Cytomegalovirus Infection Upregulates the Mitochondrial Transcription and Translation Machineries.

Karniely S, Weekes MP, Antrobus R, Rorbach J, van Haute L, Umrania Y, Smith DL, Stanton RJ, Minczuk M, Lehner PJ, Sinclair JH.

mBio. 2016 Mar 29;7(2):e00029. doi: 10.1128/mBio.00029-16.

13.

Genetic Stability of Bacterial Artificial Chromosome-Derived Human Cytomegalovirus during Culture In Vitro.

Murrell I, Wilkie GS, Davison AJ, Statkute E, Fielding CA, Tomasec P, Wilkinson GW, Stanton RJ.

J Virol. 2016 Mar 28;90(8):3929-43. doi: 10.1128/JVI.02858-15. Print 2016 Apr.

15.

Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.

Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL.

Hum Gene Ther. 2015 May;26(5):320-9. doi: 10.1089/hum.2015.015.

16.

Human cytomegalovirus: taking the strain.

Wilkinson GW, Davison AJ, Tomasec P, Fielding CA, Aicheler R, Murrell I, Seirafian S, Wang EC, Weekes M, Lehner PJ, Wilkie GS, Stanton RJ.

Med Microbiol Immunol. 2015 Jun;204(3):273-84. doi: 10.1007/s00430-015-0411-4. Epub 2015 Apr 17. Review.

17.

Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141.

Hsu JL, van den Boomen DJ, Tomasec P, Weekes MP, Antrobus R, Stanton RJ, Ruckova E, Sugrue D, Wilkie GS, Davison AJ, Wilkinson GW, Lehner PJ.

PLoS Pathog. 2015 Apr 14;11(4):e1004811. doi: 10.1371/journal.ppat.1004811. eCollection 2015 Apr.

18.

CD200 receptor restriction of myeloid cell responses antagonizes antiviral immunity and facilitates cytomegalovirus persistence within mucosal tissue.

Stack G, Jones E, Marsden M, Stacey MA, Snelgrove RJ, Lacaze P, Jacques LC, Cuff SM, Stanton RJ, Gallimore AM, Hussell T, Wilkinson GW, Ghazal P, Taylor PR, Humphreys IR.

PLoS Pathog. 2015 Feb 5;11(2):e1004641. doi: 10.1371/journal.ppat.1004641. eCollection 2015 Feb.

19.

HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells.

Stanton RJ, Prod'homme V, Purbhoo MA, Moore M, Aicheler RJ, Heinzmann M, Bailer SM, Haas J, Antrobus R, Weekes MP, Lehner PJ, Vojtesek B, Miners KL, Man S, Wilkie GS, Davison AJ, Wang ECY, Tomasec P, Wilkinson GWG.

Cell Host Microbe. 2014 Aug 13;16(2):201-214. doi: 10.1016/j.chom.2014.07.005.

20.

Quantitative temporal viromics: an approach to investigate host-pathogen interaction.

Weekes MP, Tomasec P, Huttlin EL, Fielding CA, Nusinow D, Stanton RJ, Wang EC, Aicheler R, Murrell I, Wilkinson GW, Lehner PJ, Gygi SP.

Cell. 2014 Jun 5;157(6):1460-72. doi: 10.1016/j.cell.2014.04.028.

21.

Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation.

Fielding CA, Aicheler R, Stanton RJ, Wang EC, Han S, Seirafian S, Davies J, McSharry BP, Weekes MP, Antrobus PR, Prod'homme V, Blanchet FP, Sugrue D, Cuff S, Roberts D, Davison AJ, Lehner PJ, Wilkinson GW, Tomasec P.

PLoS Pathog. 2014 May 1;10(5):e1004058. doi: 10.1371/journal.ppat.1004058. eCollection 2014 May.

22.

Functional NK cell cytotoxicity assays against virus infected cells.

Aicheler RJ, Stanton RJ.

Methods Mol Biol. 2013;1064:275-87. doi: 10.1007/978-1-62703-601-6_20.

PMID:
23996265
23.

Impact of sequence variation in the UL128 locus on production of human cytomegalovirus in fibroblast and epithelial cells.

Murrell I, Tomasec P, Wilkie GS, Dargan DJ, Davison AJ, Stanton RJ.

J Virol. 2013 Oct;87(19):10489-500. doi: 10.1128/JVI.01546-13. Epub 2013 Jul 24.

24.

Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses.

Smith W, Tomasec P, Aicheler R, Loewendorf A, Nemčovičová I, Wang EC, Stanton RJ, Macauley M, Norris P, Willen L, Ruckova E, Nomoto A, Schneider P, Hahn G, Zajonc DM, Ware CF, Wilkinson GW, Benedict CA.

Cell Host Microbe. 2013 Mar 13;13(3):324-35. doi: 10.1016/j.chom.2013.02.003.

25.

Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18.

Prod'homme V, Tomasec P, Cunningham C, Lemberg MK, Stanton RJ, McSharry BP, Wang EC, Cuff S, Martoglio B, Davison AJ, Braud VM, Wilkinson GW.

J Immunol. 2012 Mar 15;188(6):2794-804. doi: 10.4049/jimmunol.1102068. Epub 2012 Feb 15.

26.

The human cytomegalovirus UL11 protein interacts with the receptor tyrosine phosphatase CD45, resulting in functional paralysis of T cells.

Gabaev I, Steinbrück L, Pokoyski C, Pich A, Stanton RJ, Schwinzer R, Schulz TF, Jacobs R, Messerle M, Kay-Fedorov PC.

PLoS Pathog. 2011 Dec;7(12):e1002432. doi: 10.1371/journal.ppat.1002432. Epub 2011 Dec 8.

27.

Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication.

Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O, Seirafian S, McSharry BP, Neale ML, Davies JA, Tomasec P, Davison AJ, Wilkinson GW.

J Clin Invest. 2010 Sep;120(9):3191-208. doi: 10.1172/JCI42955. Epub 2010 Aug 2.

28.

Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture.

Dargan DJ, Douglas E, Cunningham C, Jamieson F, Stanton RJ, Baluchova K, McSharry BP, Tomasec P, Emery VC, Percivalle E, Sarasini A, Gerna G, Wilkinson GW, Davison AJ.

J Gen Virol. 2010 Jun;91(Pt 6):1535-46. doi: 10.1099/vir.0.018994-0.

29.

Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112.

Prod'homme V, Sugrue DM, Stanton RJ, Nomoto A, Davies J, Rickards CR, Cochrane D, Moore M, Wilkinson GWG, Tomasec P.

J Gen Virol. 2010 Aug;91(Pt 8):2034-2039. doi: 10.1099/vir.0.021931-0. Epub 2010 Apr 21.

30.

Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function.

Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW.

Biotechniques. 2008 Dec;45(6):659-62, 664-8.

31.

Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B.

McSharry BP, Burgert HG, Owen DP, Stanton RJ, Prod'homme V, Sester M, Koebernick K, Groh V, Spies T, Cox S, Little AM, Wang EC, Tomasec P, Wilkinson GW.

J Virol. 2008 May;82(9):4585-94. doi: 10.1128/JVI.02251-07. Epub 2008 Feb 20.

32.

Modulation of natural killer cells by human cytomegalovirus.

Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, McSharry BP, Rickards CR, Cochrane D, Llewellyn-Lacey S, Wang EC, Griffin CA, Davison AJ.

J Clin Virol. 2008 Mar;41(3):206-12. Review.

33.

Cytomegalovirus destruction of focal adhesions revealed in a high-throughput Western blot analysis of cellular protein expression.

Stanton RJ, McSharry BP, Rickards CR, Wang EC, Tomasec P, Wilkinson GW.

J Virol. 2007 Aug;81(15):7860-72. Epub 2007 May 23.

34.

Adenovirus vector delivery stimulates natural killer cell recognition.

Tomasec P, Wang EC, Groh V, Spies T, McSharry BP, Aicheler RJ, Stanton RJ, Wilkinson GW.

J Gen Virol. 2007 Apr;88(Pt 4):1103-8.

35.

The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells.

Prod'homme V, Griffin C, Aicheler RJ, Wang EC, McSharry BP, Rickards CR, Stanton RJ, Borysiewicz LK, López-Botet M, Wilkinson GW, Tomasec P.

J Immunol. 2007 Apr 1;178(7):4473-81.

36.

Comanagement of the patient on subcutaneous terbutaline pump therapy.

Stanton RJ.

J Nurse Midwifery. 1991 May-Jun;36(3):204-8.

PMID:
1856767

Supplemental Content

Loading ...
Support Center